当前位置: 北京消费网 > 配资开户 > 期货配资 > 正文

Abivax获准進行临床试验2019新冠肺炎候选药物ABX464

来源:互联网| 2020/5/19 18:39:55|

ANSM及人员保护委员会批准随机為1,034名2b/3期临床试验

长春配资开户      ·LIANGJIAFAGUOJIANGUANJIGOU——FAGUOGUOJIAYAOPINHEBAOJIANCHANPINANQUANSHU(ANSM)YIJIFAGUORENYUANBAOHUWEIYUANHUI(CPP)JUNYIPIZHUNABX464JINXING2b/3JIEDUAN“miR-AGE”CESHI

长春配资开户      ·KANGYANZUOYONGJIZHIKEYIYUFANGHEZHILIAODAOZHIJIXINGHUXIJIONGPOZONGHEZHENG(ARDS)HE2019XINGUANFEIYANHUANZHESIWANGDEXIBAOYINZIFENGBAOHEGUODUYANZHENG

长春配资开户      ·XINSHUJU[1]XIANSHI,ABX464ZAIRENHUXIDAOSHANGPIMOXINGZHONGYIZHISARS-CoV-2BINGDUZAITIWAIDEFUZHI,SHIABX464CHENGWEIJUYOUQIANZAISANZHONGZUOYONGDEFENZI:KANGBINGDU、KANGYANHECUJINZUZHIXIUFU。

      ·ZAIFAGUOHEOUZHOUDE50GELINCHUANGSHIYANZHONGXINDUIBINGFAZHENGGAOWEIHUANZHEJIYUZAOQIZHILIAO

长春配资开户      ·YANGE、SUIJI、ANWEIJIDUIZHAODEmiR-AGESHIYANJIANGNARU1034MINGHUANZHE,JIYUTAMENBIANJIEDEKOUFUYAOWU

      ·ZHENGZAIYUFAGUOGUOJIATOUZIYINXINGHEFAGUOTOUZIZONGMISHUCHUJIUABX464 COVID-19XIANGMUBOKUANJINXINGZUIHOUTAOLUN

      FAGUOBALI – EQS Newswire - 2020NIAN5YUE19RI - LIYONGMIANYIXITONGKAIFAYANZHENGJIBING、BINGDUJIBINGHEAIZHENGXINLIAOFADELINCHUANGJIEDUANSHENGWUJISHUGONGSI(BALIFANOUJIAOYISUOJIAOYIDAIMA:FR0012333284-ABVX)JINTIANXUANBU,QIYIHUODEFAGUOGUOJIAYAOPINHEBAOJIANCHANPINANQUANSHU(ANSM)HEFAGUORENYUANBAOHUWEIYUANHUI(CPP)DEPIZHUN,KAISHIZAI1034MING2019XINGUANFEIYANLAONIANHUOGAOWEIHUANZHEZHONGDUIABX464YUFANGDAOZHIJIXINGHUXIJIONGPOZONGHEZHENG(ARDS)DEYANZHONGYANZHENGDELIAOXIAOJINXINGYIXIANGSUIJI、SHUANGMANG、ANWEIJIDUIZHAODE2b/3QISHIYAN(miR-AGESHIYAN)。

      MEIRIKOUFUYICIABX464ZAILINGYIZHONGYANZHONGYANZHENGXINGJIBINGKUIYANGXINGJIECHANGYANDE2aQISHIYANZHONGXIANSHILELINGRENYINXIANGSHENKEDELIAOXIAO,QIDUTEDEFENZIZUOYONGJIZHIZHICHILEZHILIAO2019XINGUANFEIYANHUANZHEZHONGGUANCHADAODEXIBAOYINZIFENGBAOHECHAOYANZHENGZONGHEZHENGDELILUNJICHU。FEIBUYANZHENGSHIDAOZHIHUXIJIONGPOHEQIANZAISIWANGDEZHUYAOYUANYIN。ABX464YIJINGBEIZHENGMINGKECUJINmiR-124DEBIAOXIAN,“SHENGLIYIZHI”YANZHENG。ERXIAOFENZIHETANGHESUANmiR-124NENGYIZHIYOUGUAN2019XINGUANFEIYANXIBAOYINZIFENGBAODEDUOZHONGHUAXUEHEXIBAOYINZI,BAOKUOTNFα、IL-1β、G-CSF、IL-6、MCP-1HEIL-17。CIWAI,ABX464YUQITAZHENDUIDANGEXIBAOYINZIDEYOUXIAOKANGYANYAOBUTONG,YUZENGJIAJIHUIXINGGANRANDEYIGANXINGWUGUAN。

      CIWAI,XINDETUPOXINGSHUJU()XIANSHI,ZAIYANGEDETIWAIRENFEISHANGPIMOXINGZHONG,ABX464YIZHILESARS-CoV-2(2019XINGUANFEIYANBINGDU)DEFUZHI,SHIABX464CHENGWEIWEIYIJUYOUZHILIAO2019XINGUANFEIYANHUANZHEHUANZHESUOXUDESANZHONGZUOYONGDEHOUXUANYAOWU:KANGYAN、KANGBINGDUHEZUZHIXIUFU,ZHEIYAODEYIYUmiR-124DEGUODUBIAODA。CIWAI,FANGBIANDEKOUFUJILIANG(MEITIANYILI)RANGZHUYUANHEFEIZHUYUANHUANZHENENGJINXINGJIZAOZHILIAO。

      ZHEIXIANGYANGEDE2b/3QISHIYANJIANGZAIFAGUOHEQITAOUZHOUGUOJIADE50JIAYIYUANANZHAOGAO黄金配资 LINCHUANGBIAOZHUNJINXING,CIQIANLIUZHOUYIJINGWANCHENGLEJINZHANGDEZHUNBEIGONGZUO。ZHEIXIANGYANJIUJIANGHANGAIXUANZEHUANZHE、SUIJIHUAANWEIJIHEJIANCEYANJIU,YIJISHOUJI、GUANLISHUJUHEFENXITONGJIDEJIANQUANCHENGXU。

长春配资开户      SHIYANDEGUANJIANYAOSU:

      ·ABX464KOUFUJIYAO(MEIRI50HAOKE)DUIZHAOANWEIJIHEBIAOZHUNHULI,2BI1SUIJIFENZU

      ·1034LIGAOWEI2019XINGUANFEIYANHUANZHE(65SUIYISHANGHUOYOUWEIXIANYINSUDECHENGNIANREN)

      ·ZHAOMUQUEZHENGANRANSARS-CoV-2DEZHUYUANHEFEIZHUYUANHUANZHE。ZHAOMUGONGZUOYUJIZAIJIGEYUENEIWANCHENG

      ·ZHUYAOPINGGUBIAOZHUN:28TIANNEIWUGAOLIULIANGSHUYANGHUOFUZHUTONGQIHUOSIWANG

      ·DUOGELINCHUANGHESHENGWUXUECIYAOPINGGUZHIBIAO

      ·ZHILIAO(ABX464HUOANWEIJIHEBIAOZHUNHULI)CHIXUSHIJIAN:28TIAN

长春配资开户      ·50JIAFAGUOHEOUZHOUYIYUAN

      ZHEIXIANGYANJIUHAIJIANGJIEJUEYIXIEGUANJIANWENTI,TEBIESHIABX464ZAIYOUHUOWUWEIXIANYINSUDELAONIANHUANZHE、YOUWEIXIANYINSUDENIANQINGHUANZHEZHONGYUFANGJIXINGHUXIJIONGPOZONGHEZHENG(ARDS)DENENGLI,YIJISARS-CoV-2GANRANDUIFEIGONGNENGDECIYAOYINGXIANG。ZAIWEIJISHIQI,ZHILIAOJUECETONGCHANGJIYUXIAOXINGQIEYOUSHIWEIZHENGQUEKONGZHIDELINCHUANGSHIYAN。ZHEIXIANGYANGEJINXINGDEYANJIUZHIZAITIGONGYOUGUANABX464ZAI2019XINGUANFEIYANHUANZHEZHONGANQUANXINGHEYOUXIAOXINGDEQUANMIANLINCHUANGSHUJU。

      Abivax董事会主席兼Truffle Capital首席执行官Philippe Pouletty医学博士说:“ ABX464的miR-AGE试验已经得到法国、欧洲和美国的知名专家的认可。我们的任务是开发能改善和挽救病人生命的药物。令我感到自豪的是,我们能够利用Abivax的研究和专业知识,加入到抗击影响我们整个世界的2019新冠肺炎流行病的斗争中来。2019新冠肺炎的生理病理很复杂,我们必须对miR-AGE试验的潜在成功保持谨慎。我们希望ABX464以其独特的抗病毒、抗炎和组织修复特性,以及方便的口服给药,成为对2019新冠肺炎患者具前景的治疗方法。我要感谢一直坚持不懈致力于这个项目的伟大团队、Abivax董事会和科学咨询委员会,以及调查人员、法国国家投资银行、ANSM和CPP给予的鼎力支持与合作。在进行miR-AGE试验的同时,Abivax将继续致力于其正在进行和计划中的临床项目,特别是ABX464溃疡性结肠炎黄金配资 2b期试验的进展。”

      Abivax首席执行官Hartmut Ehrlich教授及医学博士说:“在目前没有疫苗和对2019新冠肺炎没有群体免疫的情况下,我们需要尽快找到能降低这种疾病严重程度的治疗方法。不幸的是,在治疗严重2019新冠肺炎的任何严格试验中,尚未有预防性或治疗性疗法显示出明显的疗效,因此帮助临床医生预防2019新冠肺炎患者的呼吸窘迫和死亡,并限制长期肺损伤是至关重要的。此外,减轻医院重症监护室的巨大负担是当务之急。ABX464是一种口服小分子药物,由于其独特的机理和易用性,可能有潜力实现其中一些目标。MiR-AGE ABX464试验健全、严格的设计确保我们将得出有效的科学和医学结论。如果miR-AGE试验成功,我们将与监管机构合作,以尽快推出ABX464。ABX464在临床试验中证明了治疗其他炎症性疾病是安全的。我们库存的ABX464可治疗大约5万名患者,并可在数月内扩大ABX464生产规模,惠及逾百万患者。”

      尼斯大学医院中心(CHU)的传染病学家、首席研究员Eric Cua医学博士,以及乔治·蓬皮杜欧洲医院(HEGP)的重症监护病房主任兼miR-AGE试验指导委员会主席Jean-Luc Diehl教授及医学博士长春配资开户表示:“我们完全赞同Abivax的临床试验,以评估早期应用抗炎药 ABX464是否将改善患者的预后。ABX464是一种具有新作用机制的处于后期开发阶段的化合物,特别是通过miR-124过度表达诱导抗病毒活性和抑制重要的促炎性化学和细胞因子如TNF-α、IL-6、MCP-1和IL-17,从而治疗炎症性疾病。通过在使用阿达木单抗、维多利单抗和乌司他单抗等生物制剂没有改善的患者中实现临床缓解,该分子已经在中重度溃疡性结肠炎患者中显示了转化性疗效数据。此外,ABX464在300多名志愿者和HIV或溃疡性结肠炎患者中显示出良好的安全性。基于这些数据,我们认为,对于2019新冠肺炎患者,在其发展为急性呼吸窘迫综合征之前,应进行这项稳健、双盲且得到充分支持的miR-AGE临床试验以对ABX464进行对照安慰剂和标准护理的紧急测试。”

      NISIDAXUEYIYUANZHONGXINJIQIDCRIJIANGXIEZHUAbivaxZANZHUDEGAISHIYANJINXING黄金配资 XIEDIAO,QIAOZHI·PENGPIDUOUZHOUYIYUANZHONGXINSHIYANSHIJIANGDUIHUANZHEJINXINGMIANYIHEXUEYEJIANCE。

      Abivax全球临床开发计划的最新进展:正在进行的ABX464治疗溃疡性结肠炎的2b期临床试验仍然是Abivax的首要任务。鉴于2019新冠肺炎危机和许多医院的相关紧急情况,目前预计病患招募工作将在2020年底前完成,预计2021年第二季度将取得第一批高水平成果。ABX464在类风湿性关节炎中的2a期临床研究应在2020年完成招募,预计2021年第一季度初将取得第一批高水平成果。对于Abivax正在进行的ABX196治疗肝细胞癌患者的临床试验,研究升级阶段的第一个数据可能在2021年上半年发布。

      ******

      网络直播

      AbivaxGAOJIGUANLICENGJIANGYUMEIGUODONGBUSHIJIAN2020NIAN5YUE14RIXINGQISIXIAWU2:00(BALISHIJIAN)ZHUCHIWANGLUOZHIBOHEDIANHUAHUIYI,TAOLUNZUIXIN配资开户 HEGONGSIFAZHAN,BINGJIEDAXIANGGUANWENTI。

      YUHUIZHEKEYITONGGUOWANGYELIANJIE () CANYUHUOSHIYONGYIXIAHAOMATONGGUODIANHUALIANJIE。

      电话会议

      QUERENMA: 13703843

长春配资开户      YUHUIZHEJIERUDIANHUAHUIYI:

长春配资开户      MEIGUO877-407-0792

      FAGUO0 800 912 848

      BILISHI0 800 739 04

长春配资开户      黄金配资 (SUOYOUQITAGUOJIA)1-201-689-8263

      ******

      关于Abivax

长春配资开户      AbivaxSHIYIJIALINCHUANGJIEDUANDESHENGWUJISHUGONGSI,TAZHILIYUDIAOJIERENTIDEZIRANMIANYIJIZHILAIZHILIAOZISHENMIANYIXINGJIBING、BINGDUGANRANHEAIZHENGHUANZHE。AbivaxZAIOUZHOUQIHUOJIAOYISUOBJISHICHANGGUAPAISHANGSHI(ISIN: FR0012333284 - Mnémo: ABVX)。AbivaxZONGBUWEIYUBALIHEMENGBILIAI,YOULIANGZHONGHOUXUANYAOWUCHUYULINCHUANGKAIFAJIEDUAN:ZHILIAOYANZHONGYANZHENGJIBINGDEABX464HEZHILIAOGANXIBAOAIDEABX196。

长春配资开户      GUANYUGAIGONGSIDEGENGDUO股票配资 QINGCHAYUE。ZAITwitter @ABIVAXSHANGGUANZHUWOMEN。

      关于Truffle Capital

长春配资开户      Truffle CapitalCHUANGBANYU2001NIAN,SHIYIJIADULIDEOUZHOUFENGXIANTOUZIGONGSI,ZHUANZHUYUSHENGMINGKEXUE(SHENGWUJISHUHEYILIAOJISHU)YIJIJINRONGJISHUHEBAOXIANJISHULINGYUDETUPOXINGJISHU。Truffle CapitalDESHIMINGSHIZHICHINENGGOUCHENGWEIWEILAILINGDAOZHEDENIANQINGCHUANGXINXINGGONGSIDECHUANGBANHEFAZHAN。GENGDUO股票配资 : - Twitter: @trufflecapital

      附录

      支持Abivax COVID-19 ABX464临床试验的意见领袖名单

      PD Christoph Boesecke医学博士

      DEGUOBOENDAXUEYIXUEZHONGXINGANRANYUMIANYIXUEMENZHENGAOJIYISHI

      Carol L.Brosgart教授

长春配资开户      MEIGUOJIAZHOUDAXUEJIUJINSHANFENXIAO(UCSF)YIXUE、SHENGWUTONGJIXUEHELIUXINGBINGXUELINCHUANGYIXUEBOSHI

      Eric Cua医学博士

      FAGUONISIDAXUEYIYUANZHONGXIN(CHU)GANRANKEGANRANXUEJIA、ZHUZHIYISHIYIJImiR AGE ABX464LINCHUANGYANJIUYANJIUYUAN

      Jean-Luc Diehl教授

长春配资开户      FAGUOBALIQIAOZHI·PENGPIDUOUZHOUYIYUANZHONGZHENGJIANHUBINGFANGZHUREN、YONGHUWEIYUANHUIZHUXI、YIXUEDIAOJIEYUAN、INSERM UMR_S1140CHENGYUAN,YIJImiR-AGE ABX464LINCHUANGYANJIUYANJIUYUAN

      Shahin Gharakhanian医学博士

      MEIGUOMASAZHUSAIZHOUJIANQIAOSHIShahin GharakhanianYIXUEZIXUNYOUXIANGONGSIYAOXUE、CHUANRANBINGXUEFUZEREN; MEIGUOCHUANRANBINGXUEHUIHUIYUAN; REACTing Covid-19ZIXUNWEIYUANHUICHENGYUAN。MEIGUOVERTEXZHIYAOGONGSIHEFmrFUZONGCAI。BALIDAXUEYIYUANAP-HPZHUZHIYISHI

      Christoph Huber教授

长春配资开户      QIANMEIYINCIDAXUEXUEYEZHONGLIUXIZHUREN、DEGUOMEIYINCIBioNTechLIANHECHUANGSHIRENJIANDONGSHIHUICHENGYUAN

      Vincent Jarlier教授及医学博士

      BALISAERPEITELIERYIYUANXIJUNXUEXI、YIXUEKEXUEYUANCHENGYUAN

      Bernard Malissen博士

      FAGUOMASAIMIANYIZUXUEZHONGXINZHUREN、FAGUOMASAILuminyMIANYIXUEZHONGXINDE“ TXIBAOHESHUTUZHUANGXIBAOZHENGHESHENGWUXUE”YANJIUXIAOZUZHUREN

      Jürgen Rockstroh教授及医学博士

      GAOJIYISHI,DEGUOBOENDAXUEYIXUEZHONGXINCHUANRANBINGHEMIANYIXUEMENZHENZHENSUOFUZEREN

      Lawrence R.Stanberry教授,医学博士

      MEIGUONIUYUEGELUNBIYADAXUEWAGELUOSINEIKEYISHENGJIANWAIKEYISHENGXUEYUANJIAOSHOU、黄金配资 XIANGMUFUYUANZHANG、BINGDUXUEJIA。

      Jamal Tazi教授及博士

      CNRSZHURENYIJIFAGUOMENGBILIAIAbivax-CNRSHEZUOSHIYANSHIKEXUEZHUREN

      Luc Teyton教授及医学博士

      MEIGUOJIALIFUNIYAZHOULAHUOLASHISIKELIPUSIMIANYIXUEHEWEISHENGWUXUEYANJIUBUBOSHISHENGDAOSHI。

      Jacques Thèze教授及医学博士

      YIXUEYUANYUANSHI、BASIDEYANJIUSUOQIANMIANYIXUEJIAOSHOU、FAGUOBALIDIACCURATESHOUXIZHIXINGGUAN

长春配资开户      [1] QINGCANYUEAbivaxJINTIANDIERPIAN配资开户 GAO:“ ”

      [2] EudraCT 2020-001673-75, CPP 2020.0426 bis; 20.04.24.53420

      [3] CHAOGUO1000PIANKEXUEWENZHANGJIESHILEmiR-124DUIYANZHENGDEZUOYONGJIZHI。